{"filing":{"accession_number":"0001628280-26-040447","cik":"0001576885","ticker":"ABOS","company_name":"Acumen Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"abos-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/abos-20260603.htm"},"events":[{"id":7304,"run_id":6412,"accession_number":"0001628280-26-040447","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Acumen Pharmaceuticals' June 3, 2026 annual meeting, covering three proposals: election of three Class II directors, ratification of Ernst \u0026 Young LLP as independent auditor, and approval of the Amended and Restated 2021 Equity Incentive Plan. The filing presents detailed voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.","company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":4140,"accession_number":"0001628280-26-040447","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Acumen Pharmaceuticals' June 3, 2026 annual meeting, covering three proposals: election of three Class II directors, ratification of Ernst \u0026 Young LLP as independent auditor, and approval of the Amended and Restated 2021 Equity Incentive Plan. The filing presents detailed voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:50:15.246135+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4140,"accession_number":"0001628280-26-040447","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Acumen Pharmaceuticals' June 3, 2026 annual meeting, covering three proposals: election of three Class II directors, ratification of Ernst \u0026 Young LLP as independent auditor, and approval of the Amended and Restated 2021 Equity Incentive Plan. The filing presents detailed voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:50:15.246135+00:00","company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","filing_date":"2026-06-03"}]}